Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Warp Drive Bio (Cambridge, MA) a development-stage biopharma company focused on a proprietary genomic search engine to identify and develop natural product drug candidates in microbes to target previously undruggable targests, closed a $75M Series A financing. Participants include Third Rock Ventures, Greylock Partners and Sanofi.

Sage Therapeutics (Watertown, MA) a development-stage pharmaceutical company focused on modulators of neuronal activity for schizophrenia, depression, pain and traumatic brain injury, closed a $35M Series A financing. Participants include Third Rock Ventures.

Foundation Medicine (Cambridge, MA) a development-stage diagnostic company focused on cancer genome analysis, closed a $16M Series A financing, bringing the total round to $33.5M. Participants include Kleiner Perkins Caufield & Byers, Google Ventures and Third Rock Ventures.

Topica Pharmaceuticals (Palo Alto, CA) a clinical-stage pharmaceutical company focused on treatments for onychomycosis, closed a $27M Series B financing. Participants include Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corporation.

Allena Pharmaceuticals (Newton, MA) a preclinical-stage biopharmaceutical company focused on nephrologic and urologic conditions, closed a $15M Series A financing. Participants include Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures. Thanx for your patience as we catch-up.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock. The 2Q11 OnBioVC Trend Analysis will [...]

Lotus Tissue Repair (Cambridge, MA) a development-stage biopharmaceutical company focused on dystrophic epidermolysis bullosa and other dermatologic conditions, closed a $26M Series A financing. Participants include Third Rock Ventures.

Taris Biomedical (Lexington, MA) a clinical-stage specialty pharmaceutical company focused on bladder diseases in pain, inflammation, oncology and incontinence, closed a $18.3M Series B financing. Participants include Third Rock Ventures, Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.

Blueprint Medicines (Cambridge, MA) a development-stage biopharmaceutical company focused on personalized cancer therapies, closed a $40M Series A financing. Participants include Third Rock Ventures.

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

« Previous Entries  Next Page »

to top of page...